Compare LNN & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNN | VOR |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 934.7M |
| IPO Year | 1995 | 2021 |
| Metric | LNN | VOR |
|---|---|---|
| Price | $109.07 | $14.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $113.00 | $45.33 |
| AVG Volume (30 Days) | 153.4K | ★ 815.9K |
| Earning Date | 04-02-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 12.81 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $676,368,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | $40.49 | ★ N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $97.27 | $0.17 |
| 52 Week High | $149.56 | $49.95 |
| Indicator | LNN | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 47.75 |
| Support Level | $106.63 | $11.74 |
| Resistance Level | $115.75 | $16.87 |
| Average True Range (ATR) | 3.43 | 0.97 |
| MACD | 0.28 | -0.09 |
| Stochastic Oscillator | 45.63 | 21.65 |
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.